Joseph M Blondeau

Summary

Affiliation: University of Saskatchewan
Country: Canada

Publications

  1. ncbi request reprint Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Rd, Milford, CT 06460, USA
    Expert Rev Anti Infect Ther 5:53-9. 2007
  2. pmc Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study Group
    J M Blondeau
    Division of Clinical Microbiology, Saskatoon and District Health and St Paul s Hospital Grey Nuns, and the University of Saskatchewan, Canada
    Antimicrob Agents Chemother 41:2773-5. 1997
  3. pmc Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
    J M Blondeau
    Departments of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, Saskatchewan, Canada
    Antimicrob Agents Chemother 45:433-8. 2001
  4. ncbi request reprint Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections
    J M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns and Department of Pathology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Expert Opin Investig Drugs 10:213-37. 2001
  5. ncbi request reprint Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features
    J M Blondeau
    Department of Clinical Microbiology, Royal University Hospital and the University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
    Expert Opin Pharmacother 2:317-35. 2001
  6. ncbi request reprint Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
    J M Blondeau
    Department of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, The University of Saskatchewan, Saskatchewan, S7N 0W8, Saskatoon, Canada
    Int J Antimicrob Agents 17:457-64. 2001
  7. ncbi request reprint Extended-spectrum beta-lactamases
    J M Blondeau
    Department of Clinical Microbiology, Royal University and Saskatoon City Hospitals, Saskatchewan, Canada
    Semin Respir Infect 16:169-76. 2001
  8. ncbi request reprint The role of fluoroquinolones in skin and skin structure infections
    Joseph M Blondeau
    Clinical Microbiology, Saskatoon and District Health Royal University and Saskatoon City Hospitals and St Paul s Hospital, Saskatoon, Saskatchewan, Canada
    Am J Clin Dermatol 3:37-46. 2002
  9. ncbi request reprint The macrolides
    Joseph M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Saskatoon, Saskatchewan, Canada
    Expert Opin Investig Drugs 11:189-215. 2002
  10. ncbi request reprint The evolution and role of macrolides in infectious diseases
    Joseph M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Royal University Hospital, University of Saskatchewan, Canada
    Expert Opin Pharmacother 3:1131-51. 2002

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Rd, Milford, CT 06460, USA
    Expert Rev Anti Infect Ther 5:53-9. 2007
    ..This inexorable increase is occurring in the face of a dearth of new antibiotics for community use and even fewer for treating resistant nosocomial gram-negative species. The possible strategies and consequences are discussed...
  2. pmc Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study Group
    J M Blondeau
    Division of Clinical Microbiology, Saskatoon and District Health and St Paul s Hospital Grey Nuns, and the University of Saskatchewan, Canada
    Antimicrob Agents Chemother 41:2773-5. 1997
    ..Cefoperazone activity against Pseudomonas aeruginosa was 87%, compared to 92% for ticarcillin-clavulanate. All agents had 97% or greater activity against Staphylococcus aureus...
  3. pmc Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
    J M Blondeau
    Departments of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, Saskatchewan, Canada
    Antimicrob Agents Chemother 45:433-8. 2001
    ....
  4. ncbi request reprint Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections
    J M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns and Department of Pathology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Expert Opin Investig Drugs 10:213-37. 2001
    ....
  5. ncbi request reprint Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features
    J M Blondeau
    Department of Clinical Microbiology, Royal University Hospital and the University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
    Expert Opin Pharmacother 2:317-35. 2001
    ..For example, some new compounds require once daily dosing, have minimal side effects, are active against resistant pathogens and, for some, have a lower propensity for selecting for antimicrobial resistance during patient therapy...
  6. ncbi request reprint Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
    J M Blondeau
    Department of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon District Health, The University of Saskatchewan, Saskatchewan, S7N 0W8, Saskatoon, Canada
    Int J Antimicrob Agents 17:457-64. 2001
    ..The prevalence of beta-lactamase positive H. influenzae may have decreased from levels reported in previous studies...
  7. ncbi request reprint Extended-spectrum beta-lactamases
    J M Blondeau
    Department of Clinical Microbiology, Royal University and Saskatoon City Hospitals, Saskatchewan, Canada
    Semin Respir Infect 16:169-76. 2001
    ..Additionally, some laboratories may have difficulty detecting ESBL-producing organisms. These and other issues are discussed in this article...
  8. ncbi request reprint The role of fluoroquinolones in skin and skin structure infections
    Joseph M Blondeau
    Clinical Microbiology, Saskatoon and District Health Royal University and Saskatoon City Hospitals and St Paul s Hospital, Saskatoon, Saskatchewan, Canada
    Am J Clin Dermatol 3:37-46. 2002
    ..At present, quinolones are, in general, equivalent to beta-lactam agents in the treatment of skin and soft tissue infection...
  9. ncbi request reprint The macrolides
    Joseph M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Saskatoon, Saskatchewan, Canada
    Expert Opin Investig Drugs 11:189-215. 2002
    ..While resistance is problematic, it does not always result in clinical failure. The macrolides are a valuable class of antimicrobial agent and play an important role in the management of infectious diseases...
  10. ncbi request reprint The evolution and role of macrolides in infectious diseases
    Joseph M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Royal University Hospital, University of Saskatchewan, Canada
    Expert Opin Pharmacother 3:1131-51. 2002
    ..The multitude of studies substantiating clinical as well as bacteriological success with these two agents indicates that, when used appropriately, they will stand the test of time and continue to be useful antimicrobial agents...
  11. ncbi request reprint Quinupristin/dalfopristin
    Joseph M Blondeau
    Department of Clinical Microbiology, Saskatoon and District Health and the University of Saskatchewan, Canada
    Expert Opin Pharmacother 3:1341-64. 2002
    ....
  12. ncbi request reprint In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone
    J M Blondeau
    Departments of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns, Saskatchewan, Saskatoon, Canada S7N 0W8
    Int J Antimicrob Agents 22:147-54. 2003
    ....
  13. ncbi request reprint A review of antimicrobial resistance in Canada
    J M Blondeau
    Department of Clinical Microbiology, St Paul s Hospital Grey Nuns, Saskatoon, SK, Canada
    Can J Microbiol 46:867-77. 2000
    ..In addition, future concerns and programs for ongoing surveillance are discussed...
  14. ncbi request reprint Gatifloxacin: a new fluoroquinolone
    J M Blondeau
    Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada
    Expert Opin Investig Drugs 9:1877-95. 2000
    ..Clinical trial data supports the use of gatifloxacin for treatment of patients with respiratory tract, urinary tract, skin and soft tissue infections. The side effect profile for gatifloxacin is similar to that with other agents...
  15. ncbi request reprint A review of clinical trials with fluoroquinolones with an emphasis on new agents
    J M Blondeau
    Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
    Expert Opin Investig Drugs 9:383-413. 2000
    ..These attributes, coupled with their expanded spectrum suggest that the newer fluoroquinolones are so far the most ideal agents for the empirical treatment of many common infections...
  16. ncbi request reprint In vitro evaluation of G1: a novel antimicrobial compound
    J M Blondeau
    Department of Clinical Microbiology, St Paul s Hospital Grey Nuns and Saskatoon and District Health, Saskatchewan, Canada
    Int J Antimicrob Agents 11:163-6. 1999
    ..G1 appears to be a novel antimicrobial agent with broad spectrum activity against bacterial and fungal pathogens. Defining the activity of this compound against multi-resistant bacteria is a priority...
  17. ncbi request reprint In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group
    J M Blondeau
    Division of Clinical Microbiology, Saskatoon District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Saskatoon, Canada
    J Antimicrob Chemother 43:3-23. 1999
    ..Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%...
  18. ncbi request reprint Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group
    J M Blondeau
    Saskatoon District Health and St Paul s Hospital Grey Nuns and the Department of Pathology, University of Saskatchewan, Saskatoon, Canada
    J Antimicrob Chemother 43:25-30. 1999
    ..75 and > or = 256 mg/L, respectively). This study indicates the increasing incidence, in Canada, of beta-lactamase resistance in H. influenzae and M. catarrhalis and penicillin resistance in S. pneumoniae...
  19. ncbi request reprint A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'
    J M Blondeau
    Department of Clinical Microbiology, Saskatoon District Health, St Paul s Hospital Grey Nuns, Royal University Hospital and the University of Saskatchewan, Canada
    J Antimicrob Chemother 43:1-11. 1999
    ....
  20. ncbi request reprint In vitro activity of several antimicrobial agents against 1003 isolates of Streptococcus pyogenes collected from Western Canada
    J M Blondeau
    St Paul s Hospital and Saskatoon District Health and the Department of Microbiology, University of Saskatchewan, Canada
    Int J Antimicrob Agents 12:67-70. 1999
    ..4%, clarithromycin 98.5%, clindamycin 99.9%, erythromycin 96.5% and penicillin 100%. These results indicate that antimicrobial resistance is not yet a problem of S. pyogenes in Canada...
  21. ncbi request reprint Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections
    J M Blondeau
    Saskatoon and District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Canada
    Int J Antimicrob Agents 12:145-50. 1999
    ..In this paper the formula is applied to community- and hospital-acquired urinary tract infections...
  22. ncbi request reprint In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group
    J M Blondeau
    Department of Clinical Microbiology, St Paul s Hospital Grey Nuns, Saskatchewan, Canada
    J Antimicrob Chemother 44:545-8. 1999
    ..4 and 15.6%, respectively. This in-vitro study showed that cefepime may be a useful additional agent in the treatment of infections caused by P. aeruginosa and Acinetobacter spp., but not when S. maltophilia is considered pathogenic...
  23. ncbi request reprint Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
    J M Blondeau
    Departments of Clinical Microbiology and Pathology, Saskatoon District Health, St Paul s Hospital Grey Nuns, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Canada
    Int J Antimicrob Agents 14:45-50. 2000
    ..Our data indicate that the advanced fluoroquinolones will be important compounds for treating infections caused by Gram-positive and Gram-negative pathogens...
  24. ncbi request reprint In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres. The Canadian Antimicrobial Study Group
    J M Blondeau
    Division of Clinical Microbiology, Saskatoon and District Health, Royal University Hospital, University of Sasktchewan, Canada
    Int J Antimicrob Agents 15:213-9. 2000
    ..The control of antimicrobial resistance can help maintain antibiotic usage and costs associated with the use of ever more potent drugs and the treatment of increasingly resistant infections...
  25. ncbi request reprint Antimicrobial susceptibility patterns of respiratory pathogens--a global perspective
    J M Blondeau
    Saskatoon District Health and St Paul s Hospital Grey Nuns and the University of Saskatchewan, Canada
    Semin Respir Infect 15:195-207. 2000
    ..Also, mechanisms of resistance and factors associated with the emergence, dissemination, and colonization of resistant organisms are discussed...
  26. doi request reprint Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains
    Christine K Hesje
    Department of Clinical Microbiology, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada
    J Ocul Pharmacol Ther 25:329-34. 2009
    ....
  27. ncbi request reprint Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae
    Peter Hedlin
    Department of Clinical Microbiology, Royal University Hospital and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
    Eye Contact Lens 33:161-4. 2007
    ..e., ciprofloxacin and ofloxacin) and fourth-generation (i.e., gatifloxacin and moxifloxacin) fluoroquinolone antibiotics against clinical ocular isolates of H. influenzae...
  28. pmc Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae
    Kelli Metzler
    Department of Pathology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Antimicrob Chemother 68:631-5. 2013
    ....
  29. ncbi request reprint Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa
    Glen T Hansen
    Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Int J Antimicrob Agents 27:120-4. 2006
    ..For individual isolates, the MPC correlated poorly with the minimum inhibitory concentration (r(2) = 0.41 and 0.39 for ciprofloxacin and levofloxacin, respectively)...
  30. doi request reprint Role of gemifloxacin in the management of community-acquired lower respiratory tract infections
    Joseph M Blondeau
    Department of Clinical Microbiology, Royal University Hospital and the Saskatoon Health Region, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    Int J Antimicrob Agents 31:299-306. 2008
    ..Moreover, it is generally well tolerated and is as safe as many frequently empirically prescribed antimicrobials. In addition, studies have shown gemifloxacin to be a cost-effective agent for some lower RTIs...
  31. ncbi request reprint Gemifloxacin: a new fluoroquinolone
    Joseph M Blondeau
    Department of Microbiology, Royal University Hospital, Saskatoon, Saschatchewan, Canada
    Expert Opin Pharmacother 5:1117-52. 2004
    ..Gemifloxacin is a welcomed addition to currently available agents for the treatment of community-acquired lower respiratory tract infections. Other potential indications appear to be within the spectrum of this compound...
  32. ncbi request reprint Fluoroquinolones: mechanism of action, classification, and development of resistance
    Joseph M Blondeau
    Department of Clinical Microbiology, Royal University Hospital, Saskatoon, Saskatchewan, Canada
    Surv Ophthalmol 49:S73-8. 2004
    ..This article also highlights the mechanism of resistance among common ocular pathogens and discusses the potential need for newer fluoroquinolones in ophthalmology...
  33. ncbi request reprint [Gemifloxacin for the treatment of uncomplicated urinary infections (acute cystitis)]
    Joseph M Blondeau
    Departamento de Microbiologia Clinica, Hospital de la Royal Univesity y Saskatoon Health Region, Saskatchewan, Canada
    Ginecol Obstet Mex 77:573-82. 2009
    ..Gemifloxacin showed to be safe and well tolerated. A dose a day is a safe and useful alternative amongst current empirical options to treat patients with uncomplicated urinary infections...
  34. doi request reprint New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach
    Joseph M Blondeau
    Department of Clinical Microbiology, Royal University Hospital, Canada S7N 0W8
    Vet Dermatol 20:383-96. 2009
    ..In today's environment, resistance prevention should be a goal of antimicrobial therapy...
  35. ncbi request reprint Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option
    Joseph M Blondeau
    Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan S7N 0W8, Canada
    Drugs 64:611-28. 2004
    ....
  36. ncbi request reprint Optimal antimicrobial therapy: the balance of potency and exposure
    Glenn S Tillotson
    Expert Opin Investig Drugs 15:335-7. 2006
    ....
  37. pmc Low correlation between MIC and mutant prevention concentration
    Karl Drlica
    Antimicrob Agents Chemother 50:403-4. 2006
  38. pmc Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae
    Glen T Hansen
    Antimicrob Agents Chemother 47:440-1. 2003
  39. ncbi request reprint Antimicrobial development and the risk-benefit assessment: recent adverse events and their implications
    Glenn S Tillotson
    Expert Rev Anti Infect Ther 4:515-7. 2006